Skip to content
Axe Capital logo Axe Capital Trading News

Axe Capital Investments

Clear market notes built around the JSE, the rand, and what matters locally.

Axe Capital Trading News shares simple market takes on the stories moving South African shares, the rand, and a handful of major currency pairs.

What you will find here:

1. JSE shares, South African companies, and the local knock-on effects of big market news.

2. The rand, interest rates, and a small group of forex pairs, with USD/ZAR at the centre.

3. Global stories only when they can actually change how a local investor might act.

Latest market stories

Better Artificial Intelligence Stock: Arm vs. Marvell Technology
2026-10-10 23:11 • The Motley Fool Positive Axe Cap view: Selective

The article compares Arm Holdings and Marvell Technology as AI infrastructure plays. Arm dominates smartphone processor architecture with 93.88% gross margins but faces competition from custom silicon development. Marvell leads data center connectivity with 32.6% net margins and aggressive growth targets ($20B by FY2028, $70-90B by FY2031), though it carries customer concentration risk. The author recommends Marvell as the better buy due to superior valuation metrics and stronger AI demand tailwinds.

Axe note: Marvell’s strong growth and valuation edge beats Arm’s dominance in smartphone chips for AI infrastructure exposure.

Can CoreWeave Unseat Amazon Web Services as the Top Cloud Provider?
2026-10-10 23:10 • The Motley Fool Positive Axe Cap view: Selective

CoreWeave is a rapidly growing AI-focused cloud provider expanding at 112% year-over-year, compared to AWS's 37% growth. However, AWS maintains a massive 20x size advantage with $42.2B in quarterly revenue versus CoreWeave's $2.1B. At current growth rates, it would take CoreWeave nearly seven years to match AWS's revenue. While CoreWeave presents significant upside potential if it achieves profitability comparable to AWS's 39% operating margin, it currently lacks profitability and faces execution risks.

Axe note: CoreWeave is growing fast in AI cloud but lags far behind AWS’s scale and profits, posing a risky bet for now.

Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?
2026-10-10 22:15 • The Motley Fool Positive Axe Cap view: Selective

Moderna stock has surged over 500% this year, driven by investor enthusiasm about its personalized cancer vaccine candidate. The stock now trades 61% above Wall Street's average price target. While the stock may face near-term pullback after its rapid gains, the company's strong pipeline and long-term growth potential in mRNA-based therapies suggest it remains a solid long-term biotech investment, though scaling personalized vaccines presents manufacturing challenges.

Axe note: Moderna’s stock has skyrocketed but may face turbulence despite strong long-term prospects.

What we follow

We keep the focus on JSE shares, the rand, and the currency moves that matter most to South African investors.

JSE and rand